Our top pick for
Finder may earn compensation from partners, but editorial opinions are our own. Advertiser Disclosure
Moelis & Company is a capital markets business based in the US. Moelis-and-Company shares (MC) are listed on the NYSE and all prices are listed in US Dollars. Moelis-and-Company employs 897 staff and has a trailing 12-month revenue of around 0.00.
|Latest market close||$72.20|
|52-week range||$31.73 - $72.64|
|50-day moving average||$65.19|
|200-day moving average||$58.47|
|Wall St. target price||$68.75|
|Dividend yield||$2.083 (2.89%)|
|Earnings per share (TTM)||$5.00|
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-10-20)||0.63%|
|1 month (2021-09-27)||13.25%|
|3 months (2021-07-27)||24.65%|
|6 months (2021-04-27)||26.49%|
|1 year (2020-10-26)||88.91%|
|2 years (2019-10-25)||129.06%|
|3 years (2018-10-26)||78.62%|
|5 years (2016-10-26)||189.96%|
Valuing Moelis-and-Company stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Moelis-and-Company's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Moelis-and-Company's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 14x. In other words, Moelis-and-Company shares trade at around 14x recent earnings.
That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the shares or simply that they're under-valued.
Moelis-and-Company's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.97. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Moelis-and-Company's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
|Revenue TTM||$1.3 billion|
|Operating margin TTM||35.8%|
|Gross profit TTM||$898.3 million|
|Return on assets TTM||35.19%|
|Return on equity TTM||98.29%|
|Market capitalisation||$4.9 billion|
TTM: trailing 12 months
There are currently 1.0 million Moelis-and-Company shares held short by investors – that's known as Moelis-and-Company's "short interest". This figure is 7.8% up from 940,867 last month.
There are a few different ways that this level of interest in shorting Moelis-and-Company shares can be evaluated.
Moelis-and-Company's "short interest ratio" (SIR) is the quantity of Moelis-and-Company shares currently shorted divided by the average quantity of Moelis-and-Company shares traded daily (recently around 308349.24012158). Moelis-and-Company's SIR currently stands at 3.29. In other words for every 100,000 Moelis-and-Company shares traded daily on the market, roughly 3290 shares are currently held short.
However Moelis-and-Company's short interest can also be evaluated against the total number of Moelis-and-Company shares, or, against the total number of tradable Moelis-and-Company shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Moelis-and-Company's short interest could be expressed as 0.02% of the outstanding shares (for every 100,000 Moelis-and-Company shares in existence, roughly 20 shares are currently held short) or 0.0168% of the tradable shares (for every 100,000 tradable Moelis-and-Company shares, roughly 17 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Moelis-and-Company.
Find out more about how you can short Moelis-and-Company stock.
Dividend payout ratio: 1.2% of net profits
Recently Moelis-and-Company has paid out, on average, around 1.2% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 3.35% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Moelis-and-Company shareholders could enjoy a 3.35% return on their shares, in the form of dividend payments. In Moelis-and-Company's case, that would currently equate to about $2.083 per share.
While Moelis-and-Company's payout ratio might seem low, this can signify that Moelis-and-Company is investing more in its future growth.
Moelis-and-Company's most recent dividend payout was on 16 September 2021. The latest dividend was paid out to all shareholders who bought their shares by 29 July 2021 (the "ex-dividend date").
Moelis-and-Company's shares were split on 19 June 2017.
Over the last 12 months, Moelis-and-Company's shares have ranged in value from as little as $31.7315 up to $72.64. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE average) beta is 1, while Moelis-and-Company's is 1.2111. This would suggest that Moelis-and-Company's shares are a little bit more volatile than the average for this exchange and represent, relatively-speaking, a slightly higher risk (but potentially also market-beating returns).
Moelis & Company operates as an investment banking advisory firm in the United States, Europe, and internationally. It offers advisory services in the areas of mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. The company offers its services to public multinational corporations, middle market private companies, financial sponsors, entrepreneurs, and governments. It has strategic alliances with Sumitomo Mitsui Banking Corporation and SMBC Nikko Securities Inc. ; and Alfaro, Dávila y Scherer, S. C. The company was founded in 2007 and is headquartered in New York, New York.
Steps to owning and managing ProShares Bitcoin Strategy ETF units.
Everything we know about the The Real Good Food Company IPO, plus information on how to buy in.
Everything we know about the Lulu’s Fashion Lounge Holdings IPO, plus information on how to buy in.
Everything we know about the Allarity Therapeutics IPO, plus information on how to buy in.
Everything we know about the Jupiter Neurosciences IPO, plus information on how to buy in.
Everything we know about the Mainz Biomed IPO, plus information on how to buy in.
Everything we know about the Progressive Care IPO, plus information on how to buy in.
Everything we know about the Desert Peak Minerals IPO, plus information on how to buy in.
Everything we know about the Vaxxinity IPO, plus information on how to buy in.
Everything we know about the Entrada Therapeutics IPO, plus information on how to buy in.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.